Holen Sie sich die Stockscreener-App
2.00
0.99%
-0.02
Handel nachbörslich:
2.11
0.11
+5.50%
Traws Pharma Inc Aktie (TRAW) Neueste Nachrichten
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Director at Traws Pharma (TRAW) receives grant of 33,435 stock options - Stock Titan
Traws Pharma (TRAW) director granted 31,258 stock options at $1.60 - Stock Titan
Traws Pharma (TRAW) awards 33,435 stock options to director Jack Stover - Stock Titan
Traws Pharma (TRAW) CMO awarded 108,854 stock options at $1.60 - Stock Titan
Will Traws Pharma Inc. (0T20) stock draw ESG focused fundsWeekly Profit Summary & High Accuracy Investment Signals - Naître et grandir
TRAW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cash per share of Traws Pharma, Inc. – FWB:0T20 - TradingView
TRAW SEC FilingsTraws Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Traws Pharma Reports Phase 2 COVID-19 Data, Flu Program Update - MyChesCo
Traws Pharma (NASDAQ:TRAW) Trading Down 11.2% – Here’s What Happened - Defense World
Insider Sell: How much upside does Traws Pharma Inc haveTrade Entry Report & Accurate Intraday Trading Signals - baoquankhu1.vn
TRAWTraws Pharma Latest Stock News & Market Updates - Stock Titan
Traws Pharma Reports Differentiated COVID-19 and Influenza Antiviral Progress - Contagion Live
Traws Pharma stock tumbles after FDA places tivoxavir marboxil on clinical hold By Investing.com - Investing.com South Africa
Traws Pharma stock tumbles after FDA places tivoxavir marboxil on clinical hold - Investing.com
Traws Pharma Highlights Positive Ratutrelvir Phase 2 COVID-19 Data - TipRanks
Traws Pharma Stock Plunges As FDA Halts TXM IND - RTTNews
Traws Pharma completes Phase 2 ratutrelvir analysis; tivoxavir tablet shows 28-day influenza protection potential - TradingView
Traws Pharma completes analysis of ratutrelvir clinical study in Paxlovid®-eligible and ineligible Covid-19 patients - marketscreener.com
Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid®-Eligible And Ineligible Covid-19 Patients - TradingView
Traws Pharma Reports Completed Clinical Results of Ratutrelvir Showing Differentiated Profile Compared to PAXLOVID® with Fewer Adverse Events and No Viral Rebounds - Quiver Quantitative
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza - GlobeNewswire
Ayrton Capital LLC Reduces Stake in Traws Pharma Inc - GuruFocus
Squadron funds disclose 8.9% Traws Pharma (TRAW) ownership in 13G/A filing - Stock Titan
TRAW Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Can Traws Pharma Inc. stock rebound after recent weaknessJuly 2025 Decliners & Technical Buy Zone Confirmations - mfd.ru
How rising interest rates impact Traws Pharma Inc. stockMarket Volume Summary & Free Technical Confirmation Trade Alerts - mfd.ru
Aug EndMonth: Will RSVR outperform tech stocks2025 Key Lessons & Safe Swing Trade Setups - baoquankhu1.vn
Why Traws Pharma Inc. stock could benefit from AI revolution - mfd.ru
Published on: 2026-02-03 21:55:07 - baoquankhu1.vn
Experimental COVID Pill Shows Edge Over Paxlovid as Traws Hits Key Milestones - MyChesCo
LADENBURG THALM/SH SH Upgrades Traws Pharma (NASDAQ:TRAW) to Strong-Buy - Defense World
TRAW stock slides in volatile session – what’s the latest on its phase 2 trial for COVID-19 treatment? - MSN
Traws completes enrollment in phase 2 COVID-19 drug study By Investing.com - Investing.com Canada
Traws Pharma stock soars after completing COVID-19 treatment study By Investing.com - Investing.com South Africa
Traws Pharma stock soars after completing COVID-19 treatment study - Investing.com
TRAW Stock Slides In Volatile Session – What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? - Stocktwits
Traws Pharma (TRAW) Completes Enrollment in Phase 2 COVID-19 Stu - GuruFocus
Traws Pharma Completes Phase 2 Enrollment for COVID Candidate - TipRanks
Traws completes enrollment in phase 2 COVID-19 drug study - Investing.com
COVID drug tested in Paxlovid-ineligible patients as monthly flu pill advances - stocktitan.net
Traws targets stockpile nod as COVID drug outperforms Paxlovid in trial - MSN
Wall Street Recap: Can Traws Pharma Inc outperform under higher oil prices2025 Trade Ideas & Safe Capital Growth Stock Tips - baoquankhu1.vn
Traws Pharma’s TRX-100 Phase 1 Completion: A Quiet but Key Milestone for Investors - TipRanks
Traws Targets Stockpile Nod as COVID Drug Outperforms Paxlovid in Trial - MyChesCo
Can Traws Pharma Inc. grow without dilutionOptions Play & Advanced Swing Trade Entry Alerts - bollywoodhelpline.com
Published on: 2026-01-17 06:20:37 - baoquankhu1.vn
Traws Pharma files IND for influenza treatment, updates COVID drug trial - Investing.com Nigeria
Breakout Zone: How Traws Pharma Inc stock compares to market leadersPrice Action & Risk Controlled Swing Alerts - Bộ Nội Vụ
Traws Pharma files IND for influenza treatment, updates COVID drug trial By Investing.com - Investing.com India
Traws Pharma advances flu and COVID-19 antiviral pipeline - TipRanks
Traws Pharma Files IND for Tivoxavir Marboxil and Updates Ratutrelvir Study - TradingView
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients - GlobeNewswire
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):